Mitigating ILD Following T-DXd in HR+, HER2-Low Metastatic Breast Cancer

Commentary
Video

Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.

In a conversation with CancerNetwork®, Paolo Tarantino, MD, discussed strategies for mitigating interstitial lung disease (ILD) in patients with hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer who receive fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu).

Tarantino, a clinical research fellow at Dana-Farber Cancer Institute and Harvard Medical School, spoke about this toxicity in the context of findings from the phase 3 DESTINY-Breast06 trial (NCT04494425) presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Data highlighted that 0.7% (n = 3) of patients in the T-DXd arm had grade 5 ILD or pneumonitis. Additionally, 1.6% (n = 7), 8.3% (n = 36), 0.7% (n = 3) had grade 1, 2, and 3, toxicity of this kind, respectively.

When monitoring and managing ILD in patients who receive T-DXd, Tarantino highlighted a variety of procedures such as multidisciplinary collaboration with radiologists and pulmonologists as well as management with steroids.

Transcript:

I will say that that DESTINY-Breast06 confirmed what we must know about the safety profile of T-DXd and physician’s choice of chemotherapy. One important thing is that there were still 3 cases of grade 5 fatal interstitial lung disease [ILD] in DESTINY-Breast06. It’s hard to completely get rid of those [toxicities]. It’s hard to be sure that we’re not going to see any more fatal ILD.

It’s important to keep the awareness on this [adverse] effect. We try to recommend the "Five S’s" that I found helpful to understand how to monitor and manage ILD with T-DXd. The first S is screening for the patient who you have in front of you to understand what the baseline risk is. The second [S] is remembering to scan the patients with CT scans every 6 to 12 weeks, and then [the third S is] synergy with the radiologist, pulmonologist, and the care team in order to manage ILD. [The fourth S is] suspending the drug, T-DXd, whenever ILD is suspected. [The fifth S is] introducing steroids. Those are the five S’s, and it’s very important; it can help to manage ILD.

With that said, most of the other [adverse] effects of T-DXd were very similar to what we knew. Cardiotoxicity was slightly higher in incidence; it was 8% compared with 5% or less in other trials. We know that it’s reversible, and we know that it’s low-grade, so it’s not a major concern. I do feel that we are learning how to use these drugs better. It’s always important to discuss the management of the [adverse] effects and also to develop trials to mitigate the [adverse] effects of antibody drug conjugates [ADCs]. I hope we’ll be able to develop some of these trials to mitigate ILD and maybe even other [adverse] effects with T-DXd.

Reference

Curigliano G, Hu X, Dent RA, et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): primary results from DESTINY-Breast06 (DB-06). J Clin Oncol. 2024;42(suppl 17):LBA1000. doi:10.1200/JCO.2024.42.17_suppl.LBA1000

Related Videos
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
Related Content